Cart
sales@molnova.com
GSK-LSD1 dihydrochloride (b)
CAS No. 2102933-95-7
GSK-LSD1 dihydrochloride (b)( GSK-LSD1 2HCl )
Catalog No. M27682 CAS No. 2102933-95-7
GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 62 | In Stock |
|
| 2MG | 46 | In Stock |
|
| 5MG | 62 | In Stock |
|
| 10MG | 100 | In Stock |
|
| 25MG | 210 | In Stock |
|
| 50MG | 312 | In Stock |
|
| 100MG | 511 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1088 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-LSD1 dihydrochloride (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
DescriptionGSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).(In Vitro):GSK-LSD1 induces gene expression changes in cancer cell lines with average EC50 of < 5 nM and inhibits cancer cell line growth with average EC50 of < 5 nM.
-
In VitroGSK-LSD1 shows more than 1000 fold selectivity over other closely related FAD utilizing enzymes including LSD2, and monoamine oxidases MAO-A, MAO-B. GSK-LSD1 can inhibit KDM1A/LSD1 enzyme activity. GSK-LSD1 induces the formation of LC3-II in U2OS cells. The electronic microscopy shows the formation of autophagosome with GSK-LSD1 treatment. GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns.
-
In Vivo——
-
SynonymsGSK-LSD1 2HCl
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
Recptorglucosylceramide synthase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2102933-95-7
-
Formula Weight289.24
-
Molecular FormulaC14H22Cl2N2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 62.5 mg/mL (216.08 m)
-
SMILESCl.Cl.C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47(10): p. 1277-82.
molnova catalog
related products
-
SGC-iMLLT
SGC-iMLLT is a potent and selective MLLT1/3-histone interactions inhibitor(IC50 = 0.26 μM),and is a first-in-class chemical probe displaying cellular target engagement of MLLT1(Kd = 0.129?μM) and MLLT3(Kd = 0.077?μM).
-
Dot1L-IN-4
Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor.
-
KDM2B-IN-2
KDM2B-IN-2 is a potent histone demethylase (kdm2b) inhibitor.
